Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against CarMax, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by January 2, 2026 [1][3]. Financial Performance - CarMax reported a decrease in CarMax Auto Finance income by 11.2%, attributed to a provision for loan losses of $142.2 million in Q2 of fiscal 2026, compared to $112.6 million in the same period the previous year [4]. - The provision for loan losses included an increase of $71.3 million in estimated lifetime losses on existing loans, primarily due to worsening performance among the 2022 and 2023 vintages [4]. - Following the financial results announcement, CarMax's stock price fell by $11.45 per share, approximately 20%, closing at $45.60 per share on September 26, 2025 [4]. Legal Context - The complaint alleges that CarMax and its executives made false and misleading statements regarding the company's growth prospects, which were overstated due to temporary market conditions [3]. - Investors are encouraged to contact Faruqi & Faruqi for more information regarding the class action and to discuss their legal rights [1][5].

Core Viewpoint - Molina Healthcare, Inc. has faced significant challenges, including a substantial earnings miss and a downward revision of its guidance, leading to an investigation regarding potential violations of federal securities laws [1][2]. Financial Performance - Molina reported its third quarter fiscal 2025 earnings significantly below consensus expectations, with a revised full-year earnings forecast of $14 per share, down from a previous estimate of "no less than $19" made in July [2]. - The company's marketplace business performance was identified as a key factor contributing to the earnings shortfall [2]. Stock Market Reaction - Following the earnings announcement, Molina's stock price experienced a sharp decline, falling by $38.08 to open at $157.05 per share [3]. Legal Investigation - Levi & Korsinsky has initiated an investigation into Molina Healthcare for possible violations of federal securities laws, indicating potential legal challenges ahead for the company [1]. Firm Background - Levi & Korsinsky LLP is a well-established securities litigation firm with a strong track record in representing investors and has been recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against James Hardie Industries plc due to allegations of misleading investors regarding the performance of its North America Fiber Cement segment between May 20, 2025, and August 18, 2025 [5][2]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses in James Hardie to contact them directly to discuss their legal options [1]. - A federal securities class action has been filed against James Hardie, with a deadline of December 23, 2025, for investors to seek the role of lead plaintiff [2][7]. - The complaint alleges that James Hardie and its executives violated federal securities laws by making false statements about the strength of their key segment while being aware of destocking inventory by distributors [5]. Group 2: Financial Impact - On August 19, 2025, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected fiscal 2026 earnings due to high borrowing costs [5]. - Following the announcement of these financial results, the price of James Hardie's American Depositary Receipt (ADR) fell by $9.79, or 34.44%, closing at $18.64 per ADR on August 20, 2025 [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class lawsuit on behalf all purchasers or acquirers of Six Flags Entertainment Corporation (f/k/a CopperSteel HoldCo, Inc.) (NYSE: FUN) common stock pursuant or traceable to the company’s registration statement and prospectus issued in connection with the July 1, 2024 merger of legacy Six Flags Entertainment Corporation (“Legacy Six Flags”) with Cedar Fair, L.P. (“Cedar Fair”), has been filed in ...

Nov 12, 2025 6:20 PM Eastern Standard Time Lawsuit Filed Against Stride, Inc. (LRN) After Shares Plummet Over 51% Share Investors Urged to Contact Award-Winning Firm, Gibbs Mura Then, on November 11, 2025, a class action lawsuit was filed against Stride, Inc., alleging that the company made claims that were materially false and misleading, ultimately causing harm to investors. According to the complaint, Stride represented to investors that it was "one of the nation's most successful technology- based educa ...

Core Viewpoint - RCI Hospitality Holdings, Inc. is facing legal challenges due to allegations of tax fraud and bribery, which have significantly impacted its stock price [2][3]. Group 1: Legal Issues - RCI is accused of engaging in tax fraud and bribery to conceal this fraud, leading to an understatement of the legal risks facing the company [2]. - On September 16, 2025, New York State Attorney General Letitia James announced indictments against RCI executives for a multimillion-dollar tax fraud scheme and bribery of a state tax auditor [3]. Group 2: Stock Price Impact - Following the announcement of the indictments, RCI's stock price dropped by $5.53 per share, or 16%, closing at $28.79 on September 16, 2025 [3]. - The stock continued to decline the next day, falling an additional $2.99, or 10.38%, to close at $25.80 per share on September 17, 2025 [3].

Core Insights - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. regarding alleged violations of federal securities laws related to misleading statements about the Inspire V device launch [3][6] - Investors who suffered losses from August 6, 2024, to August 4, 2025, are encouraged to contact the firm to discuss their legal options before the January 5, 2026, deadline for seeking lead plaintiff status in a federal securities class action [2][3] Company Performance - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays due to incomplete training and onboarding at treatment centers [7] - The company faced billing and reimbursement challenges, with necessary software updates for claims processing not effective until July 1, 2025, leading to continued use of the older Inspire IV system [7] - Demand for the Inspire V device was reported as weak, resulting in excess inventory and a drastic cut in 2025 earnings guidance by over 80% [8] Market Impact - Following the announcement of these issues, Inspire Medical's stock price plummeted by more than 32%, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, erasing approximately $1.2 billion in market capitalization [8]

Core Insights - Stride, Inc. is facing legal scrutiny following allegations of fraud and deceptive practices related to inflated enrollment numbers and compliance violations [5][6] - The company's stock has experienced significant declines, with a drop of 11.7% on September 15, 2025, and a further decline of up to 51% during intraday trading on October 29, 2025, following the release of disappointing financial results [6][7] Legal Issues - The Gallup-McKinley County Schools Board of Education has filed a complaint against Stride, alleging systemic violations of law and intentional misconduct [5] - The allegations include retaining "ghost students" to secure state funding and ignoring compliance requirements for employees [5] Financial Performance - In its first quarter fiscal 2026 results, Stride reported a deliberate limitation on enrollment growth due to operational issues, resulting in 10,000 to 15,000 fewer enrollments [7] - The company acknowledged "system implantation issues" that led to higher withdrawal rates and lower conversion rates, which are expected to restrict in-year enrollment growth [7]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Cytokinetics, Incorporated related to misleading statements about the New Drug Application (NDA) for aficamten, with a lead plaintiff deadline of November 17, 2025 [2][5]. Group 1: Legal Investigation - The law firm is reminding investors of the upcoming deadline to seek the role of lead plaintiff in a federal securities class action against Cytokinetics [2]. - Investors who acquired Cytokinetics securities between December 27, 2023, and May 6, 2025, are encouraged to discuss their legal rights [1][2]. Group 2: Allegations Against Cytokinetics - The complaint alleges that Cytokinetics made materially false and misleading statements regarding the NDA submission timeline and approval process for aficamten, claiming expected FDA approval in the second half of 2025 [5]. - It was revealed that the company had multiple pre-NDA meetings with the FDA but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [6]. Group 3: Impact on Investors - As a result of the misleading statements, investors purchased Cytokinetics' common stock at inflated prices and suffered significant losses when the truth was disclosed [7]. - The lead plaintiff in the class action will be the investor with the largest financial interest who can adequately represent the class [8].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against the company [2][5]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives violated federal securities laws by making false or misleading statements and failing to disclose material adverse facts regarding the company's medical cost trend assumptions [5]. - Specific allegations include a dislocation between premium rates and medical costs, dependence on low utilization of various health services for near-term growth, and the likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [6][7]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, from at least $24.50 to a range of $21.50 to $22.50, leading to a stock price drop of $6.97, or 2.9%, to close at $232.61 [7]. - On July 23, 2025, Molina further slashed its full-year 2025 earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% year-over-year decrease, and cutting its full-year adjusted earnings guidance to no less than $19.00 per diluted share, resulting in a stock price decline of $32.03, or 16.84%, to close at $158.22 [8]. Group 3: Legal Proceedings and Investor Actions - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9]. - Faruqi & Faruqi encourages anyone with information regarding Molina's conduct to contact the firm, including whistleblowers and former employees [10].